Pathogenic role of Fgf23 in Dmp1-null mice

American Journal of Physiology - Endocrinology and Metabolism

Volumn 295, Issue 2, 2008, Pages

  Liu, Shiguang ^a,c   Zhou, Jianping ^a   Tang, Wen ^a   Menard, Rochelle ^a   Feng, Jian Q ^b   Quarles, L D ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF DENTISTRY   (United States)

^c MS 3018 ^*  (United States)

Author keywords

Autosomal recessive hypophosphatemic rickets; Dentin matrix protein 1; Fibroblastic growth factor 23; Hypophosphatemia; Osteomalacia; Phosphate homeostasis

Indexed keywords

CALCITRIOL; CALCIUM; DENTIN MATRIX PROTEIN 1; FIBROBLAST GROWTH FACTOR 23; OSTEOCALCIN; PARATHYROID HORMONE; PHOSPHORUS; DMP1 PROTEIN, MOUSE; FIBROBLAST GROWTH FACTOR; PHOSPHATE; RNA; SCLEROPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOSOMAL DOMINANT HYPOPHOSPHATEMIC RICKETS; AUTOSOMAL RECESSIVE HYPOPHOSPHATEMIC RICKETS; AUTOSOMAL RECESSIVE INHERITANCE; BONE DENSITOMETRY; CONTROLLED STUDY; GENE EXPRESSION; GENE MUTATION; GENOTYPE; GROWTH RETARDATION; HISTOPATHOLOGY; HYPOPHOSPHATEMIC RICKETS; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; OSTEOCYTE; OSTEOMALACIA; PHOSPHATE METABOLISM; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VITAMIN D METABOLISM; X LINKED HYPOPHOSPHATEMIC RICKETS; ANIMAL; BLOOD; BONE DENSITY; BONE MINERALIZATION; CHEMISTRY; FEMUR; GENETICS; MALE; METABOLISM; MOUSE MUTANT; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RICKETS;

ANIMALS; BONE DENSITY; CALCIFICATION, PHYSIOLOGIC; CALCITRIOL; EXTRACELLULAR MATRIX PROTEINS; FEMUR; FIBROBLAST GROWTH FACTORS; HYPOPHOSPHATEMIC RICKETS, X-LINKED DOMINANT; MALE; MICE; MICE, KNOCKOUT; OSTEOMALACIA; PHOSPHATES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RICKETS; RNA;

EID: 52649142085     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.90201.2008     Document Type: Article

References (41)

1. No authors listed. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium. Nat Genet 11: 130-136, 1995.
2. ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 26: 345-348, 2000.
3. Almushayt A, Narayanan K, Zaki AE, George A. Dentin matrix protein 1 induces cytodifferentiation of dental pulp stem cells into odontoblasts. Gene Ther 13: 611-620, 2006.
4. Amling M, Priemel M, Holzmann T, Chapin K, Rueger JM, Baron R, Demay MB. Rescue of the skeletal phenotype of vitamin D receptor-ablated mice in the setting of normal mineral ion homeostasis: formal histomorphometric and biomechanical analyses. Endocrinology 140: 4982-4987, 1999.
5. Aono Y, Shimada T, Uamazaki Y, Hino R, Takeuchi Y, Fujita T, Fukumoto S, Nagano N, Wada M, Yamashita T. The neutralization of FGF-23 ameliorates hypophosphatemia and rickets in Hyp mice (Abstract). J Bone Miner Res 18: S16, 2003.
6. Bai X, Miao D, Li J, Goltzman D, Karaplis AC. Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology 145: 5269-5279, 2004.
7. Bai XY, Miao D, Goltzman D, Karaplis AC. The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency. J Biol Chem 278: 9843-9849, 2003.
8. Beck L, Soumounou Y, Martel J, Krishnamurthy G, Gauthier C, Goodyer CG, Tenenhouse HS. Pex/PEX tissue distribution and evidence for a deletion in the 3′ region of the Pex gene in X-linked hypophosphatemic mice. J Clin Invest 99: 1200-1209, 1997.
9. Benet-Pages A, Lorenz-Depiereux B, Zischka H, White KE, Econs MJ, Strom TM. FGF23 is processed by proprotein convertases but not by PHEX. Bone 35: 455-462, 2004.
10. Feng JQ, Huang H, Lu Y, Ye L, Xie Y, Tsutsui TW, Kunieda T, Castranio T, Scott G, Bonewald LB, Mishina Y. The Dentin matrix protein 1 (Dmp1) is specifically expressed in mineralized, but not soft, tissues during development. J Dent Res 82: 776-780, 2003.
11. Feng JQ, Ward LM, Liu S, Lu Y, Xie Y, Yuan B, Yu X, Rauch F, Davis SI, Zhang S, Rios H, Drezner MK, Quarles LD, Bonewald LF, White KE. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 38: 1310-1315, 2006.
12. Gajjeraman S, Narayanan K, Hao J, George A. Matrix macromolecules in hard tissues control the nucleation and hierarchical assembly of hydroxyapatite. J Biol Chem 282: 1193-1204, 2008.
13. Guo R, Liu S, Spurney RF, Quarles LD. Analysis of recombinant Phex: an endopeptidase in search of a substrate. Am J Physiol Endocrinol Metab 281: E837-E847, 2001.
14. He G, George A. Dentin matrix protein 1 immobilized on type I collagen fibrils facilitates apatite deposition in vitro. J Biol Chem 279: 11649-11656, 2004.
15. Imel EA, Hui SL, Econs MJ. FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets. J Bone Miner Res 22: 520-526, 2007.
16. Jadlowiec JA, Zhang X, Li J, Campbell PG, Sfeir C. Extracellular matrix-mediated signaling by dentin phosphophoryn involves activation of the Smad pathway independent of bone morphogenetic protein. J Biol Chem 281: 5341-5347, 2006.
17. Jain A, Karadag A, Fohr B, Fisher LW, Fedarko NS. Three SIBLINGs (small integrin-binding ligand, N-linked glycoproteins) enhance factor H's cofactor activity enabling MCP-like cellular evasion of complement-mediated attack. J Biol Chem 277: 13700-13708, 2002.
18. Karadag A, Fedarko NS, Fisher LW. Dentin matrix protein 1 enhances invasion potential of colon cancer cells by bridging matrix metalloproteinase-9 to integrins and CD44. Cancer Res 65: 11545-11552, 2005.
19. Larsson T, Davis SI, Garringer HJ, Mooney SD, Draman MS, Cullen MJ, White KE. Fibroblast growth factor-23 mutants causing familial tumoral calcinosis are differentially processed. Endocrinology 146: 3883-3891, 2005.
20. Larsson T, Marsell R, Schipani E, Ohlsson C, Ljunggren O, Tenenhouse HS, Juppner H, Jonsson KB. Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology 145: 3087-3094, 2004.
21. Liu S, Brown TA, Zhou J, Xiao ZS, Awad H, Guilak F, Quarles LD. Role of matrix extracellular phosphoglycoprotein in the pathogenesis of X-linked hypophosphatemia. J Am Soc Nephrol 16: 1645-1653, 2005.
22. Liu S, Guo R, Simpson LG, Xiao ZS, Burnham CE, Quarles LD. Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem 278: 37419-37426, 2003.
23. Liu S, Quarles LD. How fibroblast growth factor 23 works. J Am Soc Nephrol 18: 1637-1647, 2007.
24. Liu S, Tang W, Zhou J, Vierthaler L, Quarles LD. Distinct roles for intrinsic osteocyte abnormalities and systemic factors in regulation of FGF23 and bone mineralization in Hyp mice. Am J Physiol Endocrinol Metab 293: E1636-E1644, 2007.
25. Liu S, Zhou J, Tang W, Jiang X, Rowe DW, Quarles LD. Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab 291: E38-E49, 2006.
26. Lorenz-Depiereux B, Bastepe M, Benet-Pagès A, Amyere M, Wagenstaller J, Müller-Barth U, Badenhoop K, Kaiser SM, Rittmaster RS, Shlossberg AH, Olivares JL, Loris C, Ramos FJ, Glorieux F, Vikkula M, Jüppner H, Strom TM. DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet 38: 1248-1250, 2006.
27. Murshed M, Harmey D, Millan JL, McKee MD, Karsenty G. Unique coexpression in osteoblasts of broadly expressed genes accounts for the spatial restriction of ECM mineralization to bone. Genes Dev 19: 1093-1104, 2005.
28. Narayanan K, Ramachandran A, Hao J, He G, Park KW, Cho M, George A. Dual functional roles of dentin matrix protein 1. Implications in biomineralization and gene transcription by activation of intracellular Ca2+ store. J Biol Chem 278: 17500-17508, 2003.
29. Quarles LD. Evidence for a bone-kidney axis regulating phosphate homeostasis. J Clin Invest 112: 642-646, 2003.
30. Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K, Yamashita T. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 113: 561-568, 2004.
31. Shimada T, Urakawa I, Yamazaki Y, Hasegawa H, Hino R, Yoneya T, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T. FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun 314: 409-414, 2004.
32. Sitara D, Razzaque MS, Hesse M, Yoganathan S, Taguchi T, Erben RG, Jüppner H, Lanske B. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol 23: 421-432, 2004.
33. St-Arnaud R, Arabian A, Travers R, Barletta F, Raval-Pandya M, Chapin K, Depovere J, Mathieu C, Christakos S, Demay MB, Glorieux FH. Deficient mineralization of intramembranous bone in vitamin D-24-hydroxylase-ablated mice is due to elevated 1,25-dihydroxyvitamin D and not to the absence of 24,25-dihydroxyvitamin D. Endocrinology 141: 2658-2666, 2000.
34. Strom TM, Francis F, Lorenz B, Boddrich A, Econs MJ, Lehrach H, Meitinger T. Pex gene deletions in Gy and Hyp mice provide mouse models for X-linked hypophosphatemia. Hum Mol Genet 6: 165-171, 1997.
35. Tartaix PH, Doulaverakis M, George A, Fisher LW, Butler WT, Qin C, Salih E, Tan M, Fujimoto Y, Spevak L, Boskey AL. In vitro effects of dentin matrix protein-1 on hydroxyapatite formation provide insights into in vivo functions. J Biol Chem 279: 18115-18120, 2004.
36. Tatsuyama K, Maezawa Y, Baba H, Imamura Y, Fukuda M. Expression of various growth factors for cell proliferation and cytodifferentiation during fracture repair of bone. Eur J Histochem 44: 269-278, 2000.
37. Turner AJ, Brown CD, Carson JA, Barnes K. The neprilysin family in health and disease. Adv Exp Med Biol 477: 229-240, 2000.
38. Weber TJ, Liu S, Indridason OS, Quarles LD. Serum FGF23 levels in normal and disordered phosphorus homeostasis. J Bone Miner Res 18: 1227-1234, 2003.
39. White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM, Econs MJ. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 60: 2079-2086, 2001.
40. Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T, Fukumoto S. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 87: 4957-4960, 2002.
41. Yu X, Ibrahimi OA, Goetz R, Zhang F, Davis SI, Garringer HJ, Linhardt RJ, Ornitz DM, Mohammadi M, White KE. Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23. Endocrinology 146: 4647-4656, 2005.